Kaplan-Meier and log-rank tests revealed that patients with p-ELK1-positive non-muscle-invasive (Figure 2C) and muscle-invasive (Figure 2D) tumors had significantly higher risks for tumor recurrence (P = 0.043) and disease progression (P = 0.045)/cancer-specific mortality (P = 0.008), respectively. Here, ELK1 is linked to neoplasm.